A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new pharmacological tool capable of simultaneously administering three oligonucleotide-based drugs, each acting against a different therapeutic target within the cell.
Purespring secures $105m to start Phase I/II trial of IgAN gene therapy – Pharmaceutical Technology
Purespring will use the $105m funding to advance its lead candidate PS-002 through the clinic. Credit: Pixel-Shot via Shutterstock. Purespring Therapeutics has secured £80m ($105m)
October 9, 2024